Novo Nordisk AS (NVO)
87.65
+0.28
(+0.32%)
USD |
NYSE |
Dec 26, 16:00
89.09
+1.44
(+1.64%)
Pre-Market: 06:37
Novo Nordisk Cash from Financing (Quarterly): -2.741B for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| Evaxion Biotech AS | -- |
| Amgen Inc | -3.651B |
| Viking Therapeutics Inc | 2.522M |
| Akari Therapeutics PLC | -0.443M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 6.658B |
| Cash from Investing (Quarterly) | -3.131B |
| Free Cash Flow | 9.828B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.51% |